Pierre Fenaux

Research interests

Publications

• Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200008

• Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

  Blood · 2022 · https://doi.org/10.1182/blood.2022016867

• Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

  The Lancet Haematology · 2020 · 10.1016/s2352-3026(20)30205-2

• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

  New England Journal of Medicine · 2020 · 10.1056/nejmoa1908892

• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2012971

• Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

  Nature Medicine · 2020 · 10.1038/s41591-020-1008-z

• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

  Blood · 2019 · 10.1182/blood-2019-01-894980

• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

  Blood · 2016 · https://doi.org/10.1182/blood-2016-08-733196

• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

  Blood · 2013 · 10.1182/blood-2013-03-492884

• Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.3314

• Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

  The Lancet · 2012 · 10.1016/s0140-6736(12)60485-1

• Revised International Prognostic Scoring System for Myelodysplastic Syndromes

  Blood · 2012 · https://doi.org/10.1182/blood-2012-03-420489

• Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-235358

• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

  The Lancet Oncology · 2009 · 10.1016/s1470-2045(09)70003-8

• Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.8329

• Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

  Blood · 2008 · 10.1182/blood-2008-03-143537

• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

  Blood · 2008 · 10.1182/blood-2008-04-150250

• Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.10.050

• Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

  Blood · 2002 · 10.1182/blood-2002-03-0990

• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

  Blood · 2002 · 10.1182/blood.v100.3.1014

• A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

  Blood · 1999 · 10.1182/blood.v94.4.1192

• International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

  Blood · 1997 · https://doi.org/10.1182/blood.v89.6.2079

• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

  Blood · 1994 · 10.1182/blood.v84.9.3148.3148

• Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group

  Blood · 1993 · 10.1182/blood.v82.11.3241.3241

• All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results [see comments]

  Blood · 1990 · 10.1182/blood.v76.9.1704.1704

Current projects

No projects listed.